Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02249065 · ClinicalTrials.gov registry record · Phase 4
Mirvaso in Use Study
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 205
- Enrollment target
NCT02249065 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 205 participants.
The verdict
NCT02249065, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 205 participants
- Enrollment target
Study Summary
This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.
Interventions
- DRUG Brimonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02249065
The ClinicalTrials.gov registry entry for NCT02249065 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brimonidine is the first listed.
NCT02249065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02249065 about?
NCT02249065 is a clinical study titled "Mirvaso in Use Study". This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirv...
What is the current status of trial NCT02249065?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 205 participants. The study started on 2014-09. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02249065?
The interventions under investigation include: Brimonidine (DRUG).
Who is sponsoring clinical trial NCT02249065?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.